KEROS THERAPEUTICS INC. - COMMON STOCK

Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy

20 Aug 2025 06:48:25 By Nasdaq GlobeNewswire

Keros to Exclusively Prioritize the Clinical Advancement of KER-065

06 Aug 2025 13:15:00 By Nasdaq GlobeNewswire

Keros Therapeutics Reports Second Quarter 2025 Financial Results

06 Aug 2025 13:01:00 By Nasdaq GlobeNewswire

Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept

17 Jul 2025 05:00:00 By Nasdaq GlobeNewswire

Keros Announces Return of $375 Million in Excess Capital to Stockholders

09 Jun 2025 03:55:00 By Nasdaq GlobeNewswire

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

06 Jun 2025 13:01:00 By Nasdaq GlobeNewswire

Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring

29 May 2025 03:55:00 By Nasdaq GlobeNewswire

Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros’ Director Nominees

27 May 2025 10:45:00 By Nasdaq GlobeNewswire

Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value

19 May 2025 05:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference

12 May 2025 05:00:00 By Nasdaq GlobeNewswire

Keros Reinforces Commitment to Maximizing Stockholder Value

08 May 2025 14:31:00 By Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent First Quarter 2025 Financial Results

06 May 2025 13:01:42 By Nasdaq GlobeNewswire

Keros Therapeutics Announces Review of Strategic Alternatives

10 Apr 2025 03:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers

31 Mar 2025 03:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

28 Feb 2025 14:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

26 Feb 2025 13:01:00 By Nasdaq GlobeNewswire

Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference

30 Jan 2025 05:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept

21 Jan 2025 05:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial

15 Jan 2025 03:30:00 By Nasdaq GlobeNewswire

Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial

12 Dec 2024 03:00:00 By Nasdaq GlobeNewswire